Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiotech starts EU trial for broader indication of Vascular Wrap

This article was originally published in Clinica

Executive Summary

Pressing on with efforts to expand the potential market for its Vascular Wrap - a paclitaxel-eluting mesh - Angiotech Pharmaceuticals has begun a European trial of the device in dialysis patients with end-stage renal disease. The technology is currently awaiting EU approval for use in advanced peripheral arterial disease of the lower limbs. The 198-patient EU trial is assessing its use after surgical implantation with an ePTFE vascular graft in the upper extremity for haemodialysis vascular access; a control group of patients will receive the standard of care - an ePTFE vascular graft alone. A pivotal trial in the US is also underway for assessing the AV access indication. The Vancouver, Canada-based firm expects to use the EU trial data along with the US trial results to support a CE-mark submission.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel